Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
Recent phase I studies have reported single-agent activities of poly (ADP-ribose) polymerase (PARP) inhibitor in sporadic and in BRCA-mutant prostate cancers. Two of the most common genetic alterations in prostate cancer, ETS gene rearrangement and loss of PTEN, have been linked to increased sensiti...
Main Author: | Jingsong Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-06-01
|
Series: | Asian Journal of Andrology |
Subjects: | |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2014;volume=16;issue=3;spage=401;epage=406;aulast=Zhang |
Similar Items
-
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
by: Bijay Singh, et al.
Published: (2020-11-01) -
The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review
by: Mausam Patel, et al.
Published: (2020-03-01) -
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
by: Isabella Faraoni, et al.
Published: (2019-09-01) -
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue
by: M. Salemi, et al.
Published: (2013-04-01) -
Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy
by: Katarzyna Kluzek, et al.
Published: (2012-06-01)